



بعض الوثائق

الأصلية تالفة



SALWA AKL



بالرسالة صفحات

لم ترد بالأصل



SALWA AKL

B17024

**Diagnosis and Prediction of
Recurrence and/or Progression
of superficial Transitional Cell
Carcinoma of the Bladder**

*Essay submitted for partial fulfillment of the Master
Degree of Urology*

Presented by

Mohammed Ali Mohammed El-Naggar
M.B.B.Ch.


Under Supervision of

Prof. Dr. Mohammed Hatem El-Beyally
Professor of Urology
Faculty of Medicine-Ain Shams University

Dr. Wael Ali Maged
Assistant Professor of Urology
Faculty of Medicine-Ain Shams University

Faculty of Medicine
Ain Shams Unoversity

2001



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

"وقل العملوا فسيرى الله عملكم
ورسوله والمؤمنون"

صدق الله العظيم

سورة التوبة - آية ١٥


Acknowledgment

First; thanks are all due to *God* for blessing this work until it has reached its end as a part of his generous help throughout my life.

I would like to direct special thanks to *Prof. Dr. Mohammed Hatem El-Beyally*, professor of Urology, faculty of medicine, Ain Shams University, for the great support and encouragement he gave me throughout the whole work. It had been a great honor to work under his guidance and supervision.

I am also very grateful to *Dr. Wael Ali Maged*, assistant professor of Urology, faculty of medicine, Ain Shams University, for his close supervision, continuous help and the great effort he has done during the preparation and revision of the whole work.

Mohammed Ali El-Naggar



Index

<u>Subject</u>	<u>Page</u>
• Introduction	1
• Anatomy of the bladder	3
○ Anatomy	3
○ Blood supply	4
○ Histology	4
• Histopathology	7
○ Epithelial hyperplasia & metaplasia	7
○ Preneoplastic proliferative abnormalities	7
○ Dysplasia	8
○ Inverted papilloma	8
○ Urothelial carcinoma	9
▪ Carcinoma in situ (CIS)	9
▪ Transitional cell carcinoma (TCC)	10
• Epidemiology	13
○ Incidence	13
○ Age & sex distribution	14
○ Regional & national difference	14
○ Mortality	15
• Etiology & risk factors	17
○ Oncogenesis	18
○ Tumor suppressor genes	18
○ Cigarette smoking	18
○ Occupational exposure	19
○ Drugs	19
• Staging & grading	21
○ Tumor grading	24
• Diagnosis	27
○ Clinical picture	27
○ Laboratory findings	28
○ Imaging	32
○ Endoscopy	38
• Treatment	35
○ Surgical treatment	38
▪ Transurethral resection (TUR)	38
▪ Radical Cystectomy	40
○ Adjuvant therapies	40
▪ Radiation therapy	40

<u>Subject</u>	<u>page</u>
▪ Intravesical chemotherapy	42
▪ Intravesical immunotherapy (BCG)	49
• Mechanism of action	49
• Principles of BCG immunotherapy	50
• Efficacy of BCG	52
• Complication of BCG	53
▪ Other immunotherapeutic agents	56
○ Photodynamic therapy	58
• Prediction of recurrence &/or progression	62
○ Tumor characteristics	63
○ Pathological findings	63
○ Urine cytology	66
○ Bladder tumor antigen	67
○ Fibrin/fibrinogen degradation products	71
○ Telomeres and Telomeras	73
○ Hyaluronic acid	75
○ Nuclear Matrix Protein (NMPP22)	77
○ Biological markers	78
▪ DNA ploidy	78
○ Monoclonal antibodies	81
▪ Ki-67	81
▪ Proliferating cell nuclear antigen (PCNA)	82
○ Nuclear morphology	83
○ Cell-cycle regulators	83
○ Cyclin-dependant kinase (CDK) inhibitors	84
○ p ⁵³	84
○ Rb gene	87
○ Other biological markers	88
• Proposed algorithm	90
• Summary	91
• Reference	94
• الملخص العربي	



List of figures

<i>Figure number</i>	<i>Name</i>	<i>Page</i>
<i>Figure 1/A:</i>	Relation of the urinary bladder in male.	5
<i>Figure 1/B:</i>	Relation of the urinary bladder in female.	6
<i>Figure 2:</i>	Transitional section of the bladder.	6
<i>Figure 3:</i>	Multiple pathway in bladder cancer development.	12
<i>Figure 4:</i>	Staging of the bladder cancer.	26
<i>Figure 5:</i>	Cystoscopic view of papillary TCC of the bladder cancer.	37

1. The first part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that this is crucial for ensuring the integrity of the financial statements and for providing a clear audit trail. The text notes that any discrepancies or errors in the records can lead to significant complications during an audit and may result in the disallowance of certain expenses.


2. The second part of the document outlines the specific requirements for record-keeping. It states that all receipts, invoices, and other supporting documents must be retained for a minimum of three years. Additionally, it requires that the records be organized in a systematic and logical manner, such as by date or by category, to facilitate the audit process. The document also mentions that the records should be readily accessible to the auditor at all times.

3. The third part of the document provides guidance on how to handle situations where records are lost or damaged. It advises that the taxpayer should immediately notify the auditor and provide a written explanation of the circumstances. The document also suggests that the taxpayer should make every effort to reconstruct the missing records, such as by reviewing bank statements or other financial documents, to provide the auditor with the necessary information.

4. The final part of the document concludes by reiterating the importance of thorough record-keeping and the consequences of non-compliance. It states that failure to maintain accurate records can result in the denial of tax deductions and penalties. The document also provides a list of resources for further information, including the Internal Revenue Manual and various IRS publications.

List of tables

<i>Table number</i>	<i>Subject</i>	<i>Page</i>
<i>Table 1</i>	Occupational exposure associated with the development of bladder cancer & the possible carcinogenesis.	20
<i>Table 2</i>	ATCC & Jewett staging of bladder cancer.	23
<i>Table 3</i>	Comparison of TUR alone Vs BCG therapy.	53
<i>Table 4</i>	Intravesical chemotherapy Vs BCG.	61
<i>Table 5</i>	Potential markers of bladder cancer.	68
<i>Table 6</i>	BTA TRAK Assay sensitivity by grade & stage.	71
<i>Table 7</i>	Sensitivity & specificity of FDP.	73
<i>Table 8</i>	Sensitivity & specificity of HA, HAase, & HA-Haase tests.	76



Introduction
